Related references
Note: Only part of the references are listed.A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Andrew J. Nunn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Advances in clinical trial design for development of new TB treatments: A call for innovation
Christian Lienhardt et al.
PLOS MEDICINE (2019)
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
Patrick P. J. Phillips et al.
PLOS MEDICINE (2019)
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization
Natasha Strydom et al.
PLOS MEDICINE (2019)
Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs
Daniel L. Clemens et al.
PLOS ONE (2019)
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology
Kelly E. Dooley et al.
PLOS MEDICINE (2019)
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
Geraint Davies et al.
PLOS MEDICINE (2019)
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness
Piero L. Olliaro et al.
PLOS MEDICINE (2019)
Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons
Amita Gupta et al.
PLOS MEDICINE (2019)
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
Christian Lienhardt et al.
PLOS MEDICINE (2019)
Advances in clinical trial design for development of new TB treatments-Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam
Grania Brigden et al.
PLOS MEDICINE (2019)
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
Andrew Vernon et al.
PLOS MEDICINE (2019)
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Elin M. Svensson et al.
CLINICAL INFECTIOUS DISEASES (2018)
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Simon Tiberi et al.
LANCET INFECTIOUS DISEASES (2018)
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies
Narges Alipanah et al.
PLOS MEDICINE (2018)
State-of-the-Art Review of HIV-TB Coinfection in Special Populations
Ethel D. Weld et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Challenges of TB and HIV co-treatment: updates and insights
Jeffrey A. Tornheim et al.
CURRENT OPINION IN HIV AND AIDS (2018)
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Marjorie Z. Imperial et al.
NATURE MEDICINE (2018)
A Bayesian response-adaptive trial in tuberculosis: The endTB trial
Matteo Cellamare et al.
CLINICAL TRIALS (2017)
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree et al.
LANCET INFECTIOUS DISEASES (2017)
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response
I. H. Bartelink et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials
Lindsay McKenna et al.
CLINICAL INFECTIOUS DISEASES (2017)
Defining the Optimal Dose of Rifapentine for Pulmonary Tuberculosis: Exposure-Response Relations From Two Phase II Clinical Trials
R. M. Savic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel
Amita Gupta et al.
CLINICAL INFECTIOUS DISEASES (2016)
Challenges in the clinical assessment of novel tuberculosis drugs
Kelly E. Dooley et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
Patrick P. J. Phillips et al.
BMC MEDICINE (2016)
Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research
Christian Lienhardt et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pragmatic Trials
Ian Ford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis
Derek J. Sloan et al.
CLINICAL INFECTIOUS DISEASES (2015)
TB drug development: immunology at the table
Carl Nathan et al.
IMMUNOLOGICAL REVIEWS (2015)
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
Sharon Nachman et al.
LANCET INFECTIOUS DISEASES (2015)
The association between sterilizing activity and drug distribution into tuberculosis lesions
Brendan Prideaux et al.
NATURE MEDICINE (2015)
A Simulation Study Evaluating Bio-Creep Risk in Serial Noninferiority Clinical Trials for Preservation of Effect
K. Odem-Davis et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2015)
Randomised controlled trials for Ebola: practical and ethical issues
Clement Adebamowo et al.
LANCET (2014)
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Veronique Dartois
NATURE REVIEWS MICROBIOLOGY (2014)
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Elisabet I. Nielsen et al.
PHARMACOLOGICAL REVIEWS (2013)
Targeting Persisters for Tuberculosis Control
Ying Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Tuberculosis in Pregnant and Postpartum Women: Epidemiology, Management, and Research Gaps
Jyoti S. Mathad et al.
CLINICAL INFECTIOUS DISEASES (2012)
Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis
Patrick P. J. Phillips et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon et al.
LANCET (2012)
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
Marcus B. Conde et al.
LANCET (2009)
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting - A cluster randomized controlled trial
Sylla Thiam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment
Geraint R. Davies et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial
JN Newell et al.
LANCET (2006)
Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan
JD Walley et al.
LANCET (2001)
Share Paper
